Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.
Video content above is prompted by the following question:
Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone
August 21st 2025Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.
Read More
On the Path to Greater Precision in Treating Multiple Myeloma
August 18th 2025Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will help researchers in multiple myeloma develop a new generation of targeted therapies, decide when treatment can be stopped, and possibly screen populations for the disease.
Read More